Recent clinical evidence explores the utilization of adjuvant radiation for PDAC. According to a large-scale database study evaluating the RTOG 0848 protocol, utilization of this modality has significantly declined over the last two decades. While adjuvant radiation rates dropped from 45% to 12%, neoadjuvant radiation rates simultaneously tripled. However, researchers identified that patients with specific pathologic features still derive substantial benefits from this treatment.

Efficacy of Adjuvant Radiation for PDAC

The study utilized the National Cancer Database to analyze survival outcomes in a cohort mimicking the RTOG 0848 trial criteria. Notably, clinicians observed improved overall survival in patients with node-negative disease and positive surgical margins who received adjuvant radiation for PDAC. Specifically, median survival increased from 23.0 to 28.6 months in this high-risk group. Consequently, positive margins and nodal involvement remain the primary predictors for radiation receipt. Therefore, these findings suggest that while broad application is decreasing, targeted use remains vital for specific subgroups. Furthermore, this real-world data reinforces the importance of careful patient selection in modern oncological practice.

Is adjuvant radiation still recommended for pancreatic cancer?

While overall usage is declining in favor of neoadjuvant approaches, it remains highly beneficial for specific subgroups, particularly those with node-negative disease and positive surgical margins.

What clinical factors predict the use of adjuvant radiation?

The strongest predictors for receiving adjuvant radiation include positive surgical margins and nodal disease, as these factors typically indicate a higher risk of local recurrence.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Professional medical consultations are necessary for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Dickey EM et al. Trend of Adjuvant Radiation in Resected Pancreatic Ductal Adenocarcinoma: Evaluation of RTOG 0848 with a Large National Database. J Gastrointest Cancer. 2026 May 25. doi: undefined. PMID: 42184090.

2. Abrams RA, et al. Results of the NRG Oncology/RTOG 0848 adjuvant chemotherapy question: erlotinib + gemcitabine for resected cancer of the pancreatic head. J Clin Oncol. 2020;38(27):3139-3147.

3. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. Version 2.2024.